TEST CATALOG ORDERING & RESULTS SPECIMEN HANDLING CUSTOMER SERVICE EDUCATION & INSIGHTS
Test Catalog

Test ID: ACC    
Adrenal Mass Panel, 24 Hour, Urine

Useful For Suggests clinical disorders or settings where the test may be helpful

Aids in assessing malignancy in adrenal masses

 

May aid in improving diagnostic and prognostic prediction and dissect disease mechanisms for the following applications:

-Diagnostic assessment and follow up of adrenal cortical carcinoma (ACC)

-Differential diagnostic assessment of adrenal tumors

-Additional assessment related to Cushing syndrome, subclinical Cushing syndrome, primary aldosteronism, inborn errors of steroidogenesis, polycystic ovary syndrome

 

This test is not useful for establishing eligibility for a specific treatment as results must be interpreted in conjunction with the clinical status of the patient.

Highlights

This test offers an accurate, rapid, cost-effective, non-invasive tool to better assess malignant adrenal tumors and assists clinicians in determining whether an adrenal mass is benign or malignant.

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

Testing begins with a clinical risk assessment based on clinical data before integration with biochemical steroid data to assess the probability of a malignant adrenal cortical carcinoma (ACC) or other malignancy (sarcoma, lymphoma, other) as well as the probability of a benign mass (adenoma, myelolipoma, cyst, other).

 

Clinical data includes age at diagnosis, gender, mode of discovery and hormonal status along with tumor diameter and an unenhanced CT density measurement of the tumor (in Hounsfield units).

 

Steroids and their metabolites are extracted, analyzed, quantitated, and reported. Each reported analyte also includes a Z-score. An integrated risk assessment based on clinical data in combination with biochemical steroid data is reported to assess the probability of a malignant ACC or other malignancy as well as the probability of a benign mass.

 

See Adrenal Mass Panel Clinical Data Definition of Malignancy Predictors in Special Instructions.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Liquid Chromatography-Tandem Mass Spectrometry, High-Resolution Accurate Mass (LC-MS/MS HRAM)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

Adrenal Mass Panel, 24 Hr, U

Aliases Lists additional common names for a test, as an aid in searching

Adrenal Cortical Carcinoma
Adrenal Cortical Adenoma
Androsterone
Etiocholanolone
Dehydroepiandrosterone
16a-OH-Dehydroepiandrosterone
5-Pregnenetriol
5-Pregnenediol
Tetrahydro-11-Corticosterone
Tetrahydro-11-Deoxycorticosterone
Pregnanediol
17a-OH-Pregnanolone
Pregnanetriol
Pregnanetriolone
Tetrahydrodeoxycortisol
Cortisol
6B-OH-Cortisol
Tetrahydrocortisol
5a-Tetrahydrocortisol
B-Cortol
11B-OH-Androsterone
11B-OH-Etiocholanolone
Cortisone
Tetrahydrocortisone
a-Cortolone
B-Cortolone
11-Oxoetiocholanolone
ACC
ACCSP
Steroid
Steroid Panel
SP25
sarcoma
lymphoma
benign mass
adenoma
myelolipoma
cyst
AN
ANN
ETIO
DHEA
16a-DHEA
5PT
5PD
THB
THDOC
PD
17HP
PT
PTONE
THS
6B-OH-CORT
THF
5a-THF
11B-OH-AN
11B-OH-ET
THE
11B-OXO-ET
ACA
ACTH
Adrenocorticotropic hormone
HRAM
11B-hydroxyandrosterone
11B-hydroxyetiocholanolone
11-OXO-ET
16a-hydroxydehydroepiandrosterone
17a-hydroxypregnanolone
6B-hydroxycortisol
aCortolone
tetrahydrocorticosterone
tetrahydrodeoxycorticosterone
CAH
Hydroxylase Deficiency
CAH21
CA21H
Congenital Adrenal hyperplasia
Corticosteroids
CYP21
11Beta-OH-AN
11Beta-hydroxyandrosterone
11Beta-OH-ET
11Beta-hydroxyetiocholanolone
16alpha-DHEA
16alpha-hydroxydehydroepiandrosterone
17alpha-hydroxypregnanolone
5alpha-tetrahydrocortisol
6Beta-OH-cort
6Beta-hydroxycortisol
alpha-Cortolone
Beta-Cortol
Beta-Cortolone